Atrium Health has been granted a patent for methods and compositions involving antibodies with targeting ligands and engineered cytotoxic cells to induce cytotoxicity in cancer cells. The invention aims to deliver cytotoxic cells to cancer cells in a subject and treat cancer effectively. GlobalData’s report on Atrium Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Atrium Health - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Atrium Health, was a key innovation area identified from patents. Atrium Health's grant share as of February 2024 was 67%. Grant share is based on the ratio of number of grants to total number of patents.

Cancer treatment using antibodies and engineered cytotoxic cells

Source: United States Patent and Trademark Office (USPTO). Credit: Atrium Health

A recently granted patent (Publication Number: US11879010B2) outlines a method for inducing cytotoxicity in cancer cells in individuals with cancer, suspected of having cancer, or at risk of developing cancer. The method involves contacting the cancer cell with a specific antibody that binds to a particular antigen on the cancer cell's surface, followed by the introduction of natural killer (NK) cells that target the antibody-bound cancer cells, thereby triggering cytotoxicity in the cancer cells. This innovative approach aims to enhance the body's immune response against cancer cells, potentially improving treatment outcomes.

Furthermore, the patent describes a method for delivering NK cells to cancer cells in individuals with cancer, suspected of having cancer, or at risk of developing cancer. By utilizing a specific antibody with a targeting ligand that binds to the cancer cell's surface antigen, followed by the introduction of NK cells with a targeting agent that interacts with the antibody's ligand, the method facilitates the delivery of NK cells to the cancer cells. This targeted delivery approach could potentially enhance the efficacy of NK cell-based therapies for cancer treatment, offering a promising avenue for improving patient outcomes in the fight against cancer.

To know more about GlobalData’s detailed insights on Atrium Health, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies